Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Increased by Aviso Wealth Management

Aviso Wealth Management lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 65.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,674 shares of the biopharmaceutical company's stock after buying an additional 1,054 shares during the quarter. Regeneron Pharmaceuticals accounts for 1.0% of Aviso Wealth Management's portfolio, making the stock its 22nd biggest holding. Aviso Wealth Management's holdings in Regeneron Pharmaceuticals were worth $1,905,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of REGN. Murphy & Mullick Capital Management Corp purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $316,000. Prestige Wealth Management Group LLC raised its holdings in Regeneron Pharmaceuticals by 23.2% during the fourth quarter. Prestige Wealth Management Group LLC now owns 101 shares of the biopharmaceutical company's stock worth $72,000 after purchasing an additional 19 shares during the last quarter. Signature Estate & Investment Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 9.7% in the fourth quarter. Signature Estate & Investment Advisors LLC now owns 327 shares of the biopharmaceutical company's stock valued at $233,000 after purchasing an additional 29 shares during the last quarter. Ashton Thomas Securities LLC increased its position in shares of Regeneron Pharmaceuticals by 2.5% in the fourth quarter. Ashton Thomas Securities LLC now owns 810 shares of the biopharmaceutical company's stock valued at $577,000 after buying an additional 20 shares in the last quarter. Finally, TD Asset Management Inc. raised its stake in shares of Regeneron Pharmaceuticals by 8.9% during the 4th quarter. TD Asset Management Inc. now owns 359,389 shares of the biopharmaceutical company's stock worth $256,004,000 after buying an additional 29,322 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price target on the stock. Wells Fargo & Company cut their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research note on Friday, January 10th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their price target for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. UBS Group downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Finally, Citigroup lowered their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Up 0.2 %

Shares of NASDAQ REGN traded up $1.53 on Friday, hitting $637.36. The company had a trading volume of 805,912 shares, compared to its average volume of 673,409. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $629.02 and a 12-month high of $1,211.20. The firm has a market capitalization of $69.68 billion, a P/E ratio of 16.65, a PEG ratio of 2.34 and a beta of 0.27. The business has a 50 day moving average of $683.88 and a two-hundred day moving average of $800.34.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. During the same period in the previous year, the company posted $11.86 earnings per share. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.55%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's payout ratio is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.